GLP-1 Drugs Like Zepbound Effectively Treat Sleep Apnea Alongside CPAP

Recent research indicates that glucagon-like peptide-1 (GLP-1) medications, specifically tirzepatide (branded as Zepbound), may significantly alleviate symptoms of obstructive sleep apnea (OSA) related to obesity. A study published in the journal JAMA Otolaryngology has highlighted the potential of these medications in improving sleep apnea, a condition where the airway becomes blocked during sleep, leading to disrupted breathing.

Zepbound, which has received FDA approval specifically for treating sleep apnea, is particularly effective due to its dual action on both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is commonly prescribed for weight management, and its benefits extend to individuals struggling with sleep apnea, especially those who are overweight.

OSA occurs when the muscles in the throat relax excessively during sleep, which can obstruct the airway. While continuous positive airway pressure (CPAP) machines remain the standard treatment for OSA, weight loss is often recommended to reduce fat in the neck and throat, subsequently helping to keep the airway open. The review revealed that participants using tirzepatide experienced a notable reduction in breathing interruptions, with the apnea-hypopnea index (AHI) improving by about 20 to 24 events per hour compared to those on a placebo. Remarkably, up to half of the participants achieved complete remission of their symptoms.

The review analyzed various studies from reputable databases, including PubMed and Cochrane Library, focusing on research published between 2016 and 2025. This comprehensive examination aimed to synthesize existing knowledge on GLP-1s and their impact on sleep apnea, especially following earlier findings from the SCALE Sleep Apnea trial.

The primary mechanism through which GLP-1 receptor agonists enhance OSA symptoms seems to be weight loss, which reduces fat around the throat, neck, and tongue, thereby helping maintain open airways during sleep. Evidence suggests that losing just 10% of body weight can lead to a 26% reduction in AHI, indicating a strong link between weight management and sleep apnea improvement. Additionally, these medications may influence the brain and nerve systems that regulate breathing, though further research in humans is necessary.

Despite the promising findings, experts caution that GLP-1 medications are not a replacement for CPAP therapy. Dr. Ruchir P. Patel, a sleep medicine specialist, noted that while these drugs address the obesity risk factor in OSA, they do not resolve all anatomical issues contributing to the condition. Patients using GLP-1s should continue their CPAP treatment until a healthcare provider confirms symptom remission through a sleep study.

Dr. James J. Chao, a weight loss specialist, emphasized the importance of discussing GLP-1 therapy with healthcare professionals for those with sleep apnea. He also pointed out the cost of these medications, which can reach approximately $1,000 per month, highlighting the need for patients to explore insurance options for coverage.

As the medical community continues to investigate the long-term implications of GLP-1 treatments, these medications may provide a valuable adjunct to traditional therapies for individuals struggling with OSA, particularly those who are overweight and seeking effective management strategies.